Humboldt-Universität zu Berlin - Statistics

Humboldt-Universität zu Berlin | School of Business and Economics | Statistics | News | Symposium on AI in Digital Health (28th january 2022)

Symposium on AI in Digital Health (28th january 2022)


Artificial Intelligence in Digital Health (AIDHeal) is a network from the metropolitan Berlin-Brandenburg region that aims to address the severe shortage of expertise in the areas of data science, machine learning and digital health in Germany. AIDHeal is designed to provide a training platform for the next generation Digital Health AI experts, and to promote networking and long-term collaborations. It will serve as a springboard to intensify scientific interactions in AI, information technologies and across Digital Health Engineering research fields with the ultimate goal to enhance international visibility and competitiveness in Digital Healthcare Made in Berlin-Brandenburg.

The symposium is designed to provide an overview of AI methodology, data science, machine learning, statistics and mathematics in health. State-of-the-art AI applications in molecular medicine, translational research, population studies and in the clinic will be discussed, while future directions of AI in Digital Health will be explored. The symposium provides a testbed and springboard for local, regional, national and international collaboration with the ultimate goal to draw in and grow new talent and experts. Last but not least, the symposium will provide plenty of opportunities to engage in fruitful exchange with peers and colleagues. The symposium is tailored to attract new talents, basic scientists, engineers, digital engineering professionals, translational researchers, applied scientists, clinicians at all levels of experience and expertise. It addresses mostly but not exclusively scientists of different levels, from undergraduate and graduate students interested in AI up to trainees, advanced users, software developers and applications experts from the academic and the industrial sectors. It also targets representatives of regulatory bodies, as well as patients and citizens from organizations and the community.